RxDoctor Payments Data

Natalia Hanson, MD

Family Medicine · Mifflintown, PANPI 1851774145

Payments from drug & device makers

$1,193in general payments, 2019–2025

Across 12 payments — averaging $99.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$305
  • AstraZeneca$188
  • Jazz Pharmaceuticals Inc.$125
  • Novo Nordisk$125
  • Scpharmaceuticals Inc.$120
  • E.r. Squibb & Sons, L.L.C.$114
  • plus $216 from 3 others

What the payments were for

  • Food & beverage$1,193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,193 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$76,462
Medicare patients
371
Services billed
1,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin119$111,182
OzempicSemaglutide83$87,838
TrulicityDulaglutide62$72,640
EliquisApixaban73$56,936
RybelsusSemaglutide13$17,094
MounjaroTirzepatide16$16,397
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,900
TradjentaLinagliptin12$12,700
XareltoRivaroxaban18$12,649
MyrbetriqMirabegron19$11,882
Breo ElliptaFluticasone/Vilanterol13$10,255
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$9,888
Spiriva HandihalerTiotropium Bromide14$9,600
Incruse ElliptaUmeclidinium Bromide14$5,915
Lansoprazole36$5,509

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$100$123,883131 claims
Novo NordiskOzempic, Rybelsus$125$104,93296 claims
Lilly USA, LLCTrulicity, Mounjaro$305$89,03778 claims
Johnson & JohnsonXarelto$71$12,64918 claims
AbbVieSynthroid$45$1,69330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Mifflintown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →